Wen Kong

1.4k total citations
65 papers, 887 citations indexed

About

Wen Kong is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Wen Kong has authored 65 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 34 papers in Molecular Biology and 15 papers in Surgery. Recurrent topics in Wen Kong's work include Renal cell carcinoma treatment (48 papers), Renal and related cancers (27 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Wen Kong is often cited by papers focused on Renal cell carcinoma treatment (48 papers), Renal and related cancers (27 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Wen Kong collaborates with scholars based in China, United States and France. Wen Kong's co-authors include Jiwei Huang, Yong Huang, Jin Zhang, Wei Xue, Yonghui Chen, Baijun Dong, Jin Zhang, Yunze Xu, Wei Xue and Dongming Liu and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Wen Kong

58 papers receiving 876 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wen Kong China 18 425 401 251 236 203 65 887
Ling Guo China 16 256 0.6× 330 0.8× 224 0.9× 451 1.9× 284 1.4× 48 1.1k
Moon‐Won Yoo South Korea 17 710 1.7× 400 1.0× 352 1.4× 216 0.9× 438 2.2× 72 1.3k
Xiaoshun Shi China 17 610 1.4× 353 0.9× 297 1.2× 418 1.8× 212 1.0× 46 1.2k
Xiangqian Su China 18 594 1.4× 380 0.9× 249 1.0× 395 1.7× 324 1.6× 103 1.3k
Run‐Cong Nie China 18 439 1.0× 230 0.6× 195 0.8× 336 1.4× 248 1.2× 79 947
Marine Lefèvre France 18 424 1.0× 314 0.8× 208 0.8× 291 1.2× 214 1.1× 67 1.1k
Xiangbing Deng China 17 185 0.4× 367 0.9× 197 0.8× 524 2.2× 337 1.7× 81 1.0k
Naoko Miura Japan 17 514 1.2× 224 0.6× 125 0.5× 459 1.9× 123 0.6× 62 919
Ping’an Ding China 16 285 0.7× 436 1.1× 367 1.5× 286 1.2× 172 0.8× 68 999

Countries citing papers authored by Wen Kong

Since Specialization
Citations

This map shows the geographic impact of Wen Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen Kong more than expected).

Fields of papers citing papers by Wen Kong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen Kong. The network helps show where Wen Kong may publish in the future.

Co-authorship network of co-authors of Wen Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Wen Kong. A scholar is included among the top collaborators of Wen Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen Kong. Wen Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Jiwei, Wen Kong, Jin Zhang, et al.. (2025). A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma. The Journal of Urology. 213(6). 739–752.
2.
Qiu, Jianhui, Jingcheng Zhou, Lin Cai, et al.. (2025). Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study.. Journal of Clinical Oncology. 43(5_suppl). 534–534. 3 indexed citations
3.
4.
Wang, Xun, Jie Liu, Wen Kong, et al.. (2024). CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling. Cancer Cell International. 24(1). 147–147.
5.
Huang, Jiwei, Fan Xu, Wen Kong, et al.. (2024). Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial. Journal for ImmunoTherapy of Cancer. 12(6). e008475–e008475. 4 indexed citations
6.
Chen, Tianyi, Xiaorong Wu, Wen Kong, et al.. (2023). Serum extracellular vesicles derived hsa-miR-320d as an indicator for progression of clear cell renal cell carcinoma. Discover Oncology. 14(1). 114–114. 3 indexed citations
7.
Huang, Jiwei, Yueming Wang, Xiaoyi Hu, et al.. (2022). Surgical Management and Oncologic Outcomes for Local Retroperitoneal Recurrence of Renal Cell Carcinoma After Radical Nephrectomy. Clinical Genitourinary Cancer. 21(2). 315.e1–315.e7. 1 indexed citations
8.
Huang, Jiwei, Xiaoying Yao, Jin Zhang, et al.. (2022). Cognitive Function After Cardiopulmonary Bypass and Deep Hypothermic Circulatory Arrest in Management of Renal Cell Carcinoma With Vena Caval Thrombus. Urology. 167. 144–151. 2 indexed citations
9.
Wu, Guangyu, Jianfeng Wang, Yunze Xu, et al.. (2022). MR Spectroscopy for Detecting Fumarate Hydratase Deficiency in Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. Radiology. 305(3). 631–639. 4 indexed citations
10.
Yin, Xiaomao, et al.. (2021). Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma. OncoImmunology. 10(1). 1933332–1933332. 37 indexed citations
11.
Kong, Wen, Tongtong Yang, Xiaodong Wen, et al.. (2021). Germline Mutation Landscape and Associated Clinical Characteristics in Chinese Patients With Renal Cell Carcinoma. Frontiers in Oncology. 11. 737547–737547. 13 indexed citations
12.
Huang, Jing‐Long, et al.. (2020). Comprehensive genomic landscape in Chinese clear cell renal cell carcinoma patients. European Urology Open Science. 19. e1938–e1939. 2 indexed citations
13.
Wang, Lihe, et al.. (2018). Plasma fibrinogen as prognostic predictor in patients with metastatic renal cell carcinoma receiving target therapy. Translational Cancer Research. 7(6). 1384–1392. 5 indexed citations
14.
Cai, Wen, Jin Zhang, Yonghui Chen, et al.. (2017). Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma. Chinese Journal of Cancer. 36(1). 47–47. 7 indexed citations
15.
Wu, Guangyu, Qiuying Yao, Wen Kong, et al.. (2017). The Study of Clear Cell Renal Cell Carcinoma with MR Diffusion Kurtosis Tensor Imaging and Its Histopathologic Correlation. Academic Radiology. 25(4). 430–438. 14 indexed citations
16.
Jonasch, Eric, Gregory N. Fuller, Ian E. McCutcheon, et al.. (2017). The role of hepatocyte nuclear factor 1 homeobox B (HNF1B) loss in chromophobe RCC (ChRCC) development. Annals of Oncology. 28. v602–v602. 2 indexed citations
17.
Huang, Jiwei, Yanqing Wang, Yonghui Chen, et al.. (2017). Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Urologic Oncology Seminars and Original Investigations. 35(12). 671.e1–671.e9. 25 indexed citations
18.
Li, Mingyang, et al.. (2016). Transitional cell carcinoma with extension of the renal vein and IVC tumor thrombus: report of three cases and literature review. World Journal of Surgical Oncology. 14(1). 309–309. 8 indexed citations
19.
Wu, Xiaorong, Wei Chen, Yonghui Chen, et al.. (2016). Comparison of laparoscopic microwave ablation and radio frequency ablation assisted renal tumor enucleation for renal tumor smaller than 4 cm. Zhonghua miniao waike zazhi. 37(1). 12–16. 1 indexed citations
20.
Huang, Jiwei, Wen Kong, Yonghui Chen, et al.. (2013). Risk factors and clinical management of hemorrhage after open partial nephrectomy. Zhonghua miniao waike zazhi. 34(9). 649–652. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ling Guo Breakdown of academic impact, for papers by Moon‐Won Yoo Breakdown of academic impact, for papers by Xiaoshun Shi Breakdown of academic impact, for papers by Xiangqian Su Breakdown of academic impact, for papers by Run‐Cong Nie Breakdown of academic impact, for papers by Marine Lefèvre Breakdown of academic impact, for papers by Xiangbing Deng Breakdown of academic impact, for papers by Naoko Miura Breakdown of academic impact, for papers by Ping’an Ding
Rankless by CCL
2026